A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults.
A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic.
Jin
Xia
X
Infectious Diseases Division, University of Rochester Medical Center, Rochester, NY 14642, United States. xia jin@urmc.rochester.edu
Newman
Mark J
MJ
De-Rosa
Stephen
S
Cooper
Cristine
C
Thomas
Evan
E
Keefer
Michael
M
Fuchs
Jonathan
J
Blattner
William
W
Livingston
Brian D
BD
McKinney
Denise M
DM
Noonan
Elizabeth
E
Decamp
Allan
A
Defawe
Olivier D
OD
Wecker
Margaret
M
D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000276:immunology; D004311:Double-Blind Method; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D008875:Middle Aged; D019444:Vaccines, DNA / Q000276:immunology; D055815:Young Adult
D016915:AIDS Vaccines; D016207:Cytokines; D018984:Epitopes, T-Lymphocyte; D019444:Vaccines, DNA